×

Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium

  • US 6,511,970 B1
  • Filed: 09/28/2000
  • Issued: 01/28/2003
  • Est. Priority Date: 09/13/1996
  • Status: Expired due to Fees
First Claim
Patent Images

1. A hormonal regimen wherein at least one of the daily dosages has at least 0.5 mg of norgestrel and an estrogen component with less than 50 mcg EE equivalent.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×